Jeeva Informatics Solutions
SaaS Platform Decentralizing Clinical Research at Scale
Review of ofatumumab, Novartis’ multiple sclerosis drug (MS), has been extended by the US Food and Drug Administration (FDA) until September 2020, originally expected to occur this month.
Ofatumumab is a fully-humanised anti-CD20 monoclonal antibody (mAb) currently indicated under the brand name Arzerra as therapy for refractory chronic lymphocytic leukaemia (CLL). The drug is expected to enter the US MS market next year, as well as in the five major European markets of France, Germany, Italy, Spain and the UK, and Japan, in 2022. Read more here.
SaaS Platform Decentralizing Clinical Research at Scale
Digital Solutions for Medical Adherence and Patient Retention
Preclinical Development Services for the Pharmaceutical Industry